Therefore, we speculate that impairment of SNX1 trafficking might cause the perturbation of EGFR endocytosis, which then leads to the acquisition of gefitinib-resistance in NSCLC cell lines. The gene discussed is SNX1; the disease is non-small cell lung carcinoma.